Comparative Pharmacology
Head-to-head clinical analysis: PERIACTIN versus X TROZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERIACTIN versus X TROZINE.
PERIACTIN vs X-TROZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyproheptadine is a first-generation antihistamine with anticholinergic and antiserotonergic properties. It acts as a competitive antagonist at histamine H1 receptors and serotonin 5-HT2 receptors, thereby inhibiting histamine-mediated allergic symptoms and serotonin-mediated effects such as increased gastrointestinal motility and vascular permeability.
X-TROZINE acts as a selective serotonin reuptake inhibitor (SSRI) by binding to the serotonin transporter (SERT) and blocking reuptake of serotonin, thereby increasing serotonergic neurotransmission.
4 mg orally three times daily; adjust as needed. Maximum: 32 mg/day.
100 mg orally twice daily
None Documented
None Documented
10-12 hours terminal elimination half-life; steady-state reached in 2-3 days
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal (40-50% as metabolites, <5% unchanged); biliary/fecal (minor, ~10-20%)
Renal excretion accounts for 60-70% of total clearance, predominantly as unchanged drug. Biliary/fecal elimination constitutes 20-30% via P-glycoprotein-mediated transport. Minor metabolism (<10%) via CYP3A4.
Category C
Category C
Antihistamine
Antihistamine